---
document_datetime: 2025-12-02 04:50:19
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/pirfenidone-axunio.html
document_name: pirfenidone-axunio.html
version: success
processing_time: 0.1289169
conversion_datetime: 2025-12-28 11:41:35.746983
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Pirfenidone axunio (previously Pirfenidone AET)

[RSS](/en/individual-human-medicine.xml/67572)

##### Authorised

This medicine is authorised for use in the European Union

pirfenidone Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Pirfenidone axunio (previously Pirfenidone AET)](#news-on)
- [More information Pirfenidone](#more-information-pirfenidone-1630)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Pirfenidone axunio is a medicine used to treat adults with mild to moderate idiopathic pulmonary fibrosis (IPF). IPF is a long-term disease in which fibrous scar tissue continuously forms in the lungs, causing persistent cough, frequent lung infections and severe shortness of breath. 'Idiopathic' means that the cause of the disease is unknown.

Pirfenidone AET is a 'generic medicine'. This means that Pirfenidone AET contains the same active substance and works in the same way as a 'reference medicine' already authorised in the EU called Esbriet. For more information on generic medicines, see the question-and-answer document [here](https://www.ema.europa.eu/en/documents/medicine-qa/questions-answers-generic-medicines_en.pdf) .

Pirfenidone AET contains the active substance pirfenidone.

Expand section

Collapse section

## How is Pirfenidone axunio used?

Pirfenidone AET can only be obtained with a prescription and treatment should be started and supervised by a doctor experienced in the diagnosis and treatment of IPF.

The medicine is available as tablets (267, 534 and 801 mg) that are taken with food. The dose of Pirfenidone AET is increased steadily, starting with 267 mg three times a day in the first week, 534 mg three times a day in the second week and 801 mg three times a day from the third week onwards.

Patients who have side effects such as stomach problems, skin reactions to light or significant changes in the levels of liver enzymes may need to take a lower dose, at least temporarily.

For more information about using Pirfenidone AET, see the package leaflet or contact your doctor or pharmacist.

## How does Pirfenidone axunio work?

The mechanism of action of pirfenidone, the active substance in Pirfenidone AET, is not fully understood but it has been shown to reduce the production of fibroblasts and other substances involved in the formation of fibrous tissue during the body's tissue repair process, thereby slowing down the progression of the disease in IPF patients.

## How has Pirfenidone axunio been studied?

Studies on the benefits and risks of the active substance in the authorised use have already been carried out with the reference medicine, Esbriet, and do not need to be repeated for Pirfenidone AET.

As for every medicine, the company provided data on the quality of Pirfenidone AET. The company also carried out a study that showed that it is 'bioequivalent' to the reference medicine. Two medicines are bioequivalent when they produce the same levels of the active substance in the body and are therefore expected to have the same effect.

## What are the benefits and risks of Pirfenidone axunio

Because Pirfenidone AET is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.

## Why is Pirfenidone axunio authorised in the EU?

The European Medicines Agency concluded that, in accordance with EU requirements, Pirfenidone AET has been shown to have comparable quality and to be bioequivalent to Esbriet. Therefore, the Agency's view was that, as for Esbriet, the benefits of Pirfenidone AET outweigh the identified risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Pirfenidone axunio?

The company that markets Pirfenidone AET must ensure that all doctors who are expected to prescribe the medicine are provided with information material on skin reactions to light and changes in liver enzymes following use of Pirfenidone AET and how to minimise the risk.

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Pirfenidone AET have also been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Pirfenidone AET are continuously monitored. Suspected side effects reported with Pirfenidone AET are carefully evaluated and any necessary action taken to protect patients.

## Other information about Pirfenidone axunio

Pirfenidone AET received a marketing authorisation valid throughout the EU on 20 June 2022.

Pirfenidone AET : EPAR - Medicine overview

Reference Number: EMEA/H/C/005873/0000

English (EN) (143.64 KB - PDF)

**First published:** 28/06/2022

[View](/en/documents/overview/pirfenidone-aet-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-501)

български (BG) (167.08 KB - PDF)

**First published:**

28/06/2022

[View](/bg/documents/overview/pirfenidone-aet-epar-medicine-overview_bg.pdf)

español (ES) (134.56 KB - PDF)

**First published:**

28/06/2022

[View](/es/documents/overview/pirfenidone-aet-epar-medicine-overview_es.pdf)

čeština (CS) (165.33 KB - PDF)

**First published:**

28/06/2022

[View](/cs/documents/overview/pirfenidone-aet-epar-medicine-overview_cs.pdf)

dansk (DA) (143.04 KB - PDF)

**First published:**

28/06/2022

[View](/da/documents/overview/pirfenidone-aet-epar-medicine-overview_da.pdf)

Deutsch (DE) (146.41 KB - PDF)

**First published:**

28/06/2022

[View](/de/documents/overview/pirfenidone-aet-epar-medicine-overview_de.pdf)

eesti keel (ET) (132.39 KB - PDF)

**First published:**

28/06/2022

[View](/et/documents/overview/pirfenidone-aet-epar-medicine-overview_et.pdf)

ελληνικά (EL) (167.64 KB - PDF)

**First published:**

28/06/2022

[View](/el/documents/overview/pirfenidone-aet-epar-medicine-overview_el.pdf)

français (FR) (144.91 KB - PDF)

**First published:**

28/06/2022

[View](/fr/documents/overview/pirfenidone-aet-epar-medicine-overview_fr.pdf)

hrvatski (HR) (161.62 KB - PDF)

**First published:**

28/06/2022

[View](/hr/documents/overview/pirfenidone-aet-epar-medicine-overview_hr.pdf)

italiano (IT) (142.36 KB - PDF)

**First published:**

28/06/2022

[View](/it/documents/overview/pirfenidone-aet-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (174.35 KB - PDF)

**First published:**

28/06/2022

[View](/lv/documents/overview/pirfenidone-aet-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (163.84 KB - PDF)

**First published:**

28/06/2022

[View](/lt/documents/overview/pirfenidone-aet-epar-medicine-overview_lt.pdf)

magyar (HU) (164.67 KB - PDF)

**First published:**

28/06/2022

[View](/hu/documents/overview/pirfenidone-aet-epar-medicine-overview_hu.pdf)

Malti (MT) (167.76 KB - PDF)

**First published:**

28/06/2022

[View](/mt/documents/overview/pirfenidone-aet-epar-medicine-overview_mt.pdf)

Nederlands (NL) (143.77 KB - PDF)

**First published:**

28/06/2022

[View](/nl/documents/overview/pirfenidone-aet-epar-medicine-overview_nl.pdf)

polski (PL) (167.96 KB - PDF)

**First published:**

28/06/2022

[View](/pl/documents/overview/pirfenidone-aet-epar-medicine-overview_pl.pdf)

português (PT) (144.19 KB - PDF)

**First published:**

28/06/2022

[View](/pt/documents/overview/pirfenidone-aet-epar-medicine-overview_pt.pdf)

română (RO) (164.4 KB - PDF)

**First published:**

28/06/2022

[View](/ro/documents/overview/pirfenidone-aet-epar-medicine-overview_ro.pdf)

slovenčina (SK) (164.6 KB - PDF)

**First published:**

28/06/2022

[View](/sk/documents/overview/pirfenidone-aet-epar-medicine-overview_sk.pdf)

slovenščina (SL) (162.19 KB - PDF)

**First published:**

28/06/2022

[View](/sl/documents/overview/pirfenidone-aet-epar-medicine-overview_sl.pdf)

Suomi (FI) (141.92 KB - PDF)

**First published:**

28/06/2022

[View](/fi/documents/overview/pirfenidone-aet-epar-medicine-overview_fi.pdf)

svenska (SV) (141.76 KB - PDF)

**First published:**

28/06/2022

[View](/sv/documents/overview/pirfenidone-aet-epar-medicine-overview_sv.pdf)

Pirfenidone AET : EPAR - Risk management plan summary

English (EN) (177.47 KB - PDF)

**First published:** 28/06/2022

[View](/en/documents/rmp-summary/pirfenidone-aet-epar-risk-management-plan-summary_en.pdf)

## Product information

Pirfenidone axunio : EPAR - Product information

English (EN) (1.17 MB - PDF)

**First published:** 28/06/2022

**Last updated:** 25/04/2024

[View](/en/documents/product-information/pirfenidone-axunio-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-706)

български (BG) (1.54 MB - PDF)

**First published:**

28/06/2022

**Last updated:**

25/04/2024

[View](/bg/documents/product-information/pirfenidone-axunio-epar-product-information_bg.pdf)

español (ES) (1.15 MB - PDF)

**First published:**

28/06/2022

**Last updated:**

25/04/2024

[View](/es/documents/product-information/pirfenidone-axunio-epar-product-information_es.pdf)

čeština (CS) (1.32 MB - PDF)

**First published:**

28/06/2022

**Last updated:**

25/04/2024

[View](/cs/documents/product-information/pirfenidone-axunio-epar-product-information_cs.pdf)

dansk (DA) (988.25 KB - PDF)

**First published:**

28/06/2022

**Last updated:**

25/04/2024

[View](/da/documents/product-information/pirfenidone-axunio-epar-product-information_da.pdf)

Deutsch (DE) (831.13 KB - PDF)

**First published:**

28/06/2022

**Last updated:**

25/04/2024

[View](/de/documents/product-information/pirfenidone-axunio-epar-product-information_de.pdf)

eesti keel (ET) (1.24 MB - PDF)

**First published:**

28/06/2022

**Last updated:**

25/04/2024

[View](/et/documents/product-information/pirfenidone-axunio-epar-product-information_et.pdf)

ελληνικά (EL) (1.34 MB - PDF)

**First published:**

28/06/2022

**Last updated:**

25/04/2024

[View](/el/documents/product-information/pirfenidone-axunio-epar-product-information_el.pdf)

français (FR) (1.31 MB - PDF)

**First published:**

28/06/2022

**Last updated:**

25/04/2024

[View](/fr/documents/product-information/pirfenidone-axunio-epar-product-information_fr.pdf)

hrvatski (HR) (1.35 MB - PDF)

**First published:**

28/06/2022

**Last updated:**

25/04/2024

[View](/hr/documents/product-information/pirfenidone-axunio-epar-product-information_hr.pdf)

íslenska (IS) (1.15 MB - PDF)

**First published:**

28/06/2022

**Last updated:**

25/04/2024

[View](/is/documents/product-information/pirfenidone-axunio-epar-product-information_is.pdf)

italiano (IT) (1.17 MB - PDF)

**First published:**

28/06/2022

**Last updated:**

25/04/2024

[View](/it/documents/product-information/pirfenidone-axunio-epar-product-information_it.pdf)

latviešu valoda (LV) (1.29 MB - PDF)

**First published:**

28/06/2022

**Last updated:**

25/04/2024

[View](/lv/documents/product-information/pirfenidone-axunio-epar-product-information_lv.pdf)

lietuvių kalba (LT) (1.3 MB - PDF)

**First published:**

28/06/2022

**Last updated:**

25/04/2024

[View](/lt/documents/product-information/pirfenidone-axunio-epar-product-information_lt.pdf)

magyar (HU) (1.55 MB - PDF)

**First published:**

28/06/2022

**Last updated:**

25/04/2024

[View](/hu/documents/product-information/pirfenidone-axunio-epar-product-information_hu.pdf)

Malti (MT) (1.63 MB - PDF)

**First published:**

28/06/2022

**Last updated:**

25/04/2024

[View](/mt/documents/product-information/pirfenidone-axunio-epar-product-information_mt.pdf)

Nederlands (NL) (1.23 MB - PDF)

**First published:**

28/06/2022

**Last updated:**

25/04/2024

[View](/nl/documents/product-information/pirfenidone-axunio-epar-product-information_nl.pdf)

norsk (NO) (1.16 MB - PDF)

**First published:**

28/06/2022

**Last updated:**

25/04/2024

[View](/no/documents/product-information/pirfenidone-axunio-epar-product-information_no.pdf)

polski (PL) (1.49 MB - PDF)

**First published:**

28/06/2022

**Last updated:**

25/04/2024

[View](/pl/documents/product-information/pirfenidone-axunio-epar-product-information_pl.pdf)

português (PT) (1.18 MB - PDF)

**First published:**

28/06/2022

**Last updated:**

25/04/2024

[View](/pt/documents/product-information/pirfenidone-axunio-epar-product-information_pt.pdf)

română (RO) (1.31 MB - PDF)

**First published:**

28/06/2022

**Last updated:**

25/04/2024

[View](/ro/documents/product-information/pirfenidone-axunio-epar-product-information_ro.pdf)

slovenčina (SK) (1.54 MB - PDF)

**First published:**

28/06/2022

**Last updated:**

25/04/2024

[View](/sk/documents/product-information/pirfenidone-axunio-epar-product-information_sk.pdf)

slovenščina (SL) (1.69 MB - PDF)

**First published:**

28/06/2022

**Last updated:**

25/04/2024

[View](/sl/documents/product-information/pirfenidone-axunio-epar-product-information_sl.pdf)

Suomi (FI) (1.04 MB - PDF)

**First published:**

28/06/2022

**Last updated:**

25/04/2024

[View](/fi/documents/product-information/pirfenidone-axunio-epar-product-information_fi.pdf)

svenska (SV) (1.22 MB - PDF)

**First published:**

28/06/2022

**Last updated:**

25/04/2024

[View](/sv/documents/product-information/pirfenidone-axunio-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** IAIN/0008 18/04/2024

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Pirfenidone axunio : EPAR - All Authorised Presentations

English (EN) (75.17 KB - PDF)

**First published:** 28/06/2022

**Last updated:** 09/09/2022

[View](/en/documents/all-authorised-presentations/pirfenidone-axunio-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-524)

български (BG) (88.63 KB - PDF)

**First published:**

28/06/2022

**Last updated:**

09/09/2022

[View](/bg/documents/all-authorised-presentations/pirfenidone-axunio-epar-all-authorised-presentations_bg.pdf)

español (ES) (75.8 KB - PDF)

**First published:**

28/06/2022

**Last updated:**

09/09/2022

[View](/es/documents/all-authorised-presentations/pirfenidone-axunio-epar-all-authorised-presentations_es.pdf)

čeština (CS) (81.03 KB - PDF)

**First published:**

28/06/2022

**Last updated:**

09/09/2022

[View](/cs/documents/all-authorised-presentations/pirfenidone-axunio-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (75.64 KB - PDF)

**First published:**

28/06/2022

**Last updated:**

09/09/2022

[View](/da/documents/all-authorised-presentations/pirfenidone-axunio-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (76.8 KB - PDF)

**First published:**

28/06/2022

**Last updated:**

09/09/2022

[View](/de/documents/all-authorised-presentations/pirfenidone-axunio-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (79.09 KB - PDF)

**First published:**

28/06/2022

**Last updated:**

09/09/2022

[View](/et/documents/all-authorised-presentations/pirfenidone-axunio-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (83.02 KB - PDF)

**First published:**

28/06/2022

**Last updated:**

09/09/2022

[View](/el/documents/all-authorised-presentations/pirfenidone-axunio-epar-all-authorised-presentations_el.pdf)

français (FR) (76.96 KB - PDF)

**First published:**

28/06/2022

**Last updated:**

09/09/2022

[View](/fr/documents/all-authorised-presentations/pirfenidone-axunio-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (77.94 KB - PDF)

**First published:**

28/06/2022

**Last updated:**

09/09/2022

[View](/hr/documents/all-authorised-presentations/pirfenidone-axunio-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (76.71 KB - PDF)

**First published:**

28/06/2022

**Last updated:**

09/09/2022

[View](/is/documents/all-authorised-presentations/pirfenidone-axunio-epar-all-authorised-presentations_is.pdf)

italiano (IT) (74.7 KB - PDF)

**First published:**

28/06/2022

**Last updated:**

09/09/2022

[View](/it/documents/all-authorised-presentations/pirfenidone-axunio-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (79.35 KB - PDF)

**First published:**

28/06/2022

**Last updated:**

09/09/2022

[View](/lv/documents/all-authorised-presentations/pirfenidone-axunio-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (80.04 KB - PDF)

**First published:**

28/06/2022

**Last updated:**

09/09/2022

[View](/lt/documents/all-authorised-presentations/pirfenidone-axunio-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (80.97 KB - PDF)

**First published:**

28/06/2022

**Last updated:**

09/09/2022

[View](/hu/documents/all-authorised-presentations/pirfenidone-axunio-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (80.66 KB - PDF)

**First published:**

28/06/2022

**Last updated:**

09/09/2022

[View](/mt/documents/all-authorised-presentations/pirfenidone-axunio-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (73.89 KB - PDF)

**First published:**

28/06/2022

**Last updated:**

09/09/2022

[View](/nl/documents/all-authorised-presentations/pirfenidone-axunio-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (75.6 KB - PDF)

**First published:**

28/06/2022

**Last updated:**

09/09/2022

[View](/no/documents/all-authorised-presentations/pirfenidone-axunio-epar-all-authorised-presentations_no.pdf)

polski (PL) (78.54 KB - PDF)

**First published:**

28/06/2022

**Last updated:**

09/09/2022

[View](/pl/documents/all-authorised-presentations/pirfenidone-axunio-epar-all-authorised-presentations_pl.pdf)

português (PT) (75.57 KB - PDF)

**First published:**

28/06/2022

**Last updated:**

09/09/2022

[View](/pt/documents/all-authorised-presentations/pirfenidone-axunio-epar-all-authorised-presentations_pt.pdf)

română (RO) (78.27 KB - PDF)

**First published:**

28/06/2022

**Last updated:**

09/09/2022

[View](/ro/documents/all-authorised-presentations/pirfenidone-axunio-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (80.29 KB - PDF)

**First published:**

28/06/2022

**Last updated:**

09/09/2022

[View](/sk/documents/all-authorised-presentations/pirfenidone-axunio-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (77.6 KB - PDF)

**First published:**

28/06/2022

**Last updated:**

09/09/2022

[View](/sl/documents/all-authorised-presentations/pirfenidone-axunio-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (74.5 KB - PDF)

**First published:**

28/06/2022

**Last updated:**

09/09/2022

[View](/fi/documents/all-authorised-presentations/pirfenidone-axunio-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (74.26 KB - PDF)

**First published:**

28/06/2022

**Last updated:**

09/09/2022

[View](/sv/documents/all-authorised-presentations/pirfenidone-axunio-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Pirfenidone axunio (previously Pirfenidone AET) Active substance Pirfenidone International non-proprietary name (INN) or common name pirfenidone Therapeutic area (MeSH) Idiopathic Pulmonary Fibrosis Anatomical therapeutic chemical (ATC) code L04AX05

### Pharmacotherapeutic group

Immunosuppressants

### Therapeutic indication

Pirfenidone AET is indicated in adults for the treatment of mild to moderate idiopathic pulmonary fibrosis (IPF).

## Authorisation details

EMA product number EMEA/H/C/005873

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Marketing authorisation holder

Axunio Pharma GmbH

Van-der-Smissen-Straße 1

Opinion adopted 22/04/2022 Marketing authorisation issued 20/06/2022 Revision 4

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Pirfenidone axunio : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (111.84 KB - PDF)

**First published:** 09/09/2022

**Last updated:** 25/04/2024

[View](/en/documents/procedural-steps-after/pirfenidone-axunio-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

## Initial marketing authorisation documents

Pirfenidone AET : EPAR - Public Assessment Report

Reference Number: EMA/609423/2022

English (EN) (387.39 KB - PDF)

**First published:** 28/06/2022

[View](/en/documents/assessment-report/pirfenidone-aet-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Pirfenidone AET

Adopted

Reference Number: EMA/CHMP/215096/2022

English (EN) (128.61 KB - PDF)

**First published:** 22/04/2022

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-pirfenidone-aet_en.pdf)

#### News on Pirfenidone axunio (previously Pirfenidone AET)

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 19-22 April 2022](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-19-22-april-2022) 22/04/2022

#### More information Pirfenidone

Questions and answers on generic medicines

Reference Number: EMA/393905/2006 Rev. 2

English (EN) (66.45 KB - PDF)

**First published:** 09/07/2007

**Last updated:** 07/12/2012

[View](/en/documents/other/questions-and-answers-generic-medicines_en.pdf)

[Other languages (22)](#file-language-dropdown-211)

български (BG) (93.16 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/bg/documents/other/questions-and-answers-generic-medicines_bg.pdf)

español (ES) (68.3 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/es/documents/other/questions-and-answers-generic-medicines_es.pdf)

čeština (CS) (87.71 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/cs/documents/other/questions-and-answers-generic-medicines_cs.pdf)

dansk (DA) (66.79 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/da/documents/other/questions-and-answers-generic-medicines_da.pdf)

Deutsch (DE) (67.55 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/de/documents/other/questions-and-answers-generic-medicines_de.pdf)

eesti keel (ET) (65.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/et/documents/other/questions-and-answers-generic-medicines_et.pdf)

ελληνικά (EL) (91.29 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/el/documents/other/questions-and-answers-generic-medicines_el.pdf)

français (FR) (68.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fr/documents/other/questions-and-answers-generic-medicines_fr.pdf)

hrvatski (HR) (87.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hr/documents/other/questions-and-answers-generic-medicines_hr.pdf)

italiano (IT) (67.62 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/it/documents/other/questions-and-answers-generic-medicines_it.pdf)

latviešu valoda (LV) (111.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lv/documents/other/questions-and-answers-generic-medicines_lv.pdf)

lietuvių kalba (LT) (86.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lt/documents/other/questions-and-answers-generic-medicines_lt.pdf)

magyar (HU) (85.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hu/documents/other/questions-and-answers-generic-medicines_hu.pdf)

Malti (MT) (89.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/mt/documents/other/questions-and-answers-generic-medicines_mt.pdf)

Nederlands (NL) (66.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/nl/documents/other/questions-and-answers-generic-medicines_nl.pdf)

polski (PL) (88.51 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pl/documents/other/questions-and-answers-generic-medicines_pl.pdf)

português (PT) (68.32 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pt/documents/other/questions-and-answers-generic-medicines_pt.pdf)

română (RO) (86.9 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/ro/documents/other/questions-and-answers-generic-medicines_ro.pdf)

slovenčina (SK) (87.73 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sk/documents/other/questions-and-answers-generic-medicines_sk.pdf)

slovenščina (SL) (84.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sl/documents/other/questions-and-answers-generic-medicines_sl.pdf)

Suomi (FI) (66.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fi/documents/other/questions-and-answers-generic-medicines_fi.pdf)

svenska (SV) (67.11 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sv/documents/other/questions-and-answers-generic-medicines_sv.pdf)

**This page was last updated on** 25/04/2024

## Share this page

[Back to top](#main-content)